NEW YORK (GenomeWeb) – PGXL Technologies today said that it has formed a partnership with NX PharmaGen under which the partners have created a research center focused on exosome analysis.

The PGXL NeXosome Center of Excellence will utilize NX PharmaGen's NeXosome microparticle enrichment technology to support identification of biomarkers. The partners said they will provide access to the platform and assay development services in a CLIA setting to researchers and biopharmaceutical firms.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: variant linked to canine cleft lip, new compression tool, and more.

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.

Fareed Zakaria writes that instead of focusing solely on STEM-related courses, students would do well to pursue the liberal arts if they want to be technology innovators.

A Harvard Business Review study found four major patterns of gender biases and added that black and Latina scientists further had to navigate racial stereotypes.